Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatic fibrogenesis].

Kwan Sik Lee1

  • 1Department of Internal Medicine, Yonsei University College of Medicine, Gangnam-Gu, Seoul, Korea. leeks519@yumc.yonsei.ac.kr

The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi
|November 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy in Patients With Chronic Hepatitis B.

Liver international : official journal of the International Association for the Study of the Liver·2024
Same author

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.

Clinical and molecular hepatology·2024
Same author

Extrahepatic Malignancies Are the Leading Cause of Death in Patients with Chronic Hepatitis B without Cirrhosis: A Large Population-Based Cohort Study.

Cancers·2024
Same author

Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report.

Journal of liver cancer·2023
Same author

The care cascade for hepatitis C virus and prognosis of chronic hepatitis C patients treated with antiviral agents in a tertiary hospital.

BMC gastroenterology·2023
Same author

Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals.

Journal of viral hepatitis·2022

Chronic liver injury leads to hepatic fibrosis and cirrhosis due to excessive extracellular matrix (ECM) production by hepatic stellate cells (HSC). Inhibiting HSC activation is key to preventing fibrosis progression.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Pathogenesis of Liver Disease

Context:

  • Acute liver injury typically resolves without scarring.
  • Chronic liver injury causes excessive extracellular matrix (ECM) production, leading to hepatic fibrosis.
  • Hepatic fibrosis can progress to irreversible liver cirrhosis, a major cause of mortality.

Purpose:

  • To investigate the characteristics of hepatic stellate cells (HSC) in hepatic fibrogenesis.
  • To identify potential therapeutic targets for inhibiting HSC activation and preventing liver fibrosis progression.
  • To explore novel agents for antifibrogenic therapy.

Summary:

  • Hepatic stellate cells (HSC) are central to hepatic fibrosis pathogenesis through excessive ECM production.
  • HSC activation is influenced by factors like oxidative stress, acetaldehyde, and TGF-beta.

Related Experiment Videos

  • Inhibiting HSC activation is a primary strategy to block liver fibrosis progression.

    • Impact:

    • Understanding HSC behavior is crucial for developing effective antifibrogenic agents.
    • This research aims to identify therapeutic strategies to prevent the progression of liver disease to cirrhosis.
    • Potential antifibrogenic agents include antioxidants, retinoids, flavonoids, and PPAR-gamma agonists.